Efficacy of erythropoietin-stimulating medications in controlling anemia in CKD patients

Abstract

Iron deficiency, chronic inflammation, and decreased endogenous erythropoietin production are the main causes of anemia, a prevalent and crippling consequence of chronic kidney disease (CKD). To raise hemoglobin levels, lower the requirement for blood transfusions, and improve patient quality of life, erythropoietin-stimulating agents (ESAs) are now a mainstay in the treatment of CKD-associated anemia. This study evaluates the efficacy of erythropoietin-stimulating medications in treating anemia in patients with chronic kidney disease. Hemoglobin response, transfusion needs, and clinical improvement were examined as part of a thorough evaluation of CKD patients on ESA therapy. The results show that, when properly dosed and managed, ESA medication dramatically raises and keeps hemoglobin concentrations within therapeutic levels.